Cell-Penetrating Peptides for Cytosolic delivery Of biomacromolecules

Weissig/Organelle-Specific Nanotechnology

Volumn , Issue , 2010, Pages 403-432

  Foged, Camilla ^a   Jing, Xiaona ^a   Nielsen, Hanne Moerck ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84858782931     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470875780.ch22     Document Type: Chapter

References (158)

1. Frankel, A. D. and Pabo, C. O. Cellular uptake of the tat protein from human immunodefi ciency virus. Cell 55 (6): 1189-1193 (1988).
2. Green, M. and Loewenstein, P. M. Autonomous functional domains of chemically synthesized human immunodefi ciency virus tat trans-activator protein. Cell 55 (6): 1179-1188 (1988).
3. Joliot, A., et al. Antennapedia homeobox peptide regulates neural morphogenesis. Proc. Nat. Acad. Sci. U.S.A. 88 (5): 1864-1868 (1991).
4. Vives, E., Brodin, P., and Lebleu, B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272 (25): 16010-16017 (1997).
5. Derossi, D., et al. The 3Rd helix of the antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. 269 (14): 10444-10450 (1994).
6. Fawell, S., et al. Tat-mediated delivery of heterologous proteins into cells. Proc. Nat. Acad. Sci. U.S.A. 91 (2): 664-668 (1994).
7. Richard, J. P., et al. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J. Biol. Chem. 278 (1): 585-590 (2003).
8. Schwarze, S. R., et al. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285 (5433): 1569-1572 (1999).
9. Futaki, S., et al. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J. Biol. Chem. 276 (8): 5836-5840 (2001).
10. Pooga, M., et al. Cell penetration by transportan. FASEB J. 12 (1): 67-77 (1998).
11. Morris, M. C., et al. A new peptide vector for effi cient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res. 25 (14): 2730-2736 (1997).
12. Morris, M. C., et al. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat. Biotechnol. 19 (12): 1173-1176 (2001).
13. Lindgren, M., et al. Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide. Biochem. Pharmacol. 71 (4): 416-425 (2006).
14. Hansen, M., Kilk, K., and Langel, U. Predicting cell-penetrating peptides. Adv. Drug Deliv. Rev. 60 (4-5): 572-579 (2008).
15. Wagstaff, K. M. and Jans, D. A. Protein transduction: cell penetrating peptides and their therapeutic applications. Curr. Med. Chem. 13 (12): 1371-1387 (2006).
16. Pujals, S., et al. Mechanistic aspects of CPP-mediated intracellular drug delivery: relevance of CPP self-assembly. Biochim. Biophys. Acta. 1758 (3): 264-279 (2006).
17. Myrberg, H., Lindgren, M., and Langel, U. Protein delivery by the cell-penetrating peptide YTA2. Bioconjug. Chem. 18 (1): 170-174 (2007).
18. Gros, E., et al. A non-covalent peptide-based strategy for protein and peptide nucleic acid transduction. Biochim. Biophys. Acta 1758 (3): 384-393 (2006).
19. Hallbrink, M., et al. Cargo delivery kinetics of cell-penetrating peptides. Biochim. Biophys. Acta 1515 (2): 101-109 (2001).
20. Silhol, M., et al. Different mechanisms for cellular internalization of the HIV-1 Tat-derived cell penetrating peptide and recombinant proteins fused to Tat. Eur. J. Biochem. 269 (2): 494-501 (2002).
21. Jones, S. W., et al. Characterisation of cell-penetrating peptide-mediated peptide delivery. Bri. J. Pharmacol. 145 (8): 1093-1102 (2005).
22. Cardozo, A. K., et al. Cell-permeable peptides induce dose-and length-dependent cytotoxic effects. Biochim. Biophys. Acta 1768 (9): 2222-2234 (2007).
23. Zorko, M. and Langel, U. Cell-penetrating peptides: mechanism and kinetics of cargo delivery. Adv. Drug Deliv. Rev. 57 (4): 529-545 (2005).
24. Barany-Wallje, E., et al. Differential membrane perturbation caused by the cell penetrating peptide Tp10 depending on attached cargo. FEBS Lett. 581 (13): 2389-2393 (2007).
25. El Andaloussi, S., Holm, T., and Langel, U. Cell-penetrating peptides: mechanisms and applications. Curr. Pharm. Design 11 (28): 3597-3611 (2005).
26. Gupta, B., Levchenko, T. S., and Torchilin, V. P. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv. Drug Deliv. Rev. 57 (4): 637-651 (2005).
27. Smith, M. W. and Gumbleton, M. Endocytosis at the blood-brain barrier: from basic understanding to drug delivery strategies. J. Drug Target. 14 (4): 191-214 (2006).
28. Mae, M. and Langel, U. Cell-penetrating peptides as vectors for peptide. protein and oligonucleotide delivery. Curr. Opin. Pharmacol. 6 (5): 509-514 (2006).
29. Chauhan, A., et al. The taming of the cell penetrating domain of the HIV Tat: myths and realities. J. Control. Release 117 (2): 148-162 (2007).
30. Squier, M. K. and Cohen, J. J. Cell-mediated cytotoxic mechanisms. Curr. Opin. Immunol. 6 (3): 447-452 (1994).
31. Shastri, N., Schwab, S., and Serwold, T. Producing nature's gene-chips: the generation of peptides for display by MHC class I molecules. Annu. Rev. Immunol. 20: 463-493 (2002).
32. Bouvier, M. Accessory proteins and the assembly of human class I MHC molecules: a molecular and structural perspective. Mol. Immunol. 39 (12): 697-706 (2003).
33. Yewdell, J. W., Norbury, C. C., and Bennink, J. R. Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8+T cell responses to infectious agents. tumors. transplants. and vaccines. Adv. Immunol. 73: 1-77 (1999).
34. Pfeifer, J. D., et al. Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature 361 (6410): 359-362 (1993).
35. Kovacsovics-Bankowski, M., et al. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc. Nat. Acad. Sci. U.S.A. 90 (11): 4942-4946 (1993).
36. Norbury, C. C., et al. Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells. Eur. J. Immunol. 27 (1): 280-288 (1997).
37. Regnault, A., et al. Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J. Exp. Med. 189 (2): 371-380 (1999).
38. Rodriguez, A., et al. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat. Cell Biol. 1 (6): 362-368 (1999).
39. Kim, D. T., et al. Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide. J. Immunol. 159 (4): 1666-1668 (1997).
40. Shibagaki, N. and Udey, M. C. Dendritic cells transduced with TAT protein transduction domain-containing tyrosinase-related protein 2 vaccinate against murine melanoma. Eur. J. Immunol. 33 (4): 850-860 (2003).
41. Tacken, P. J., et al. No advantage of cell-penetrating peptides over receptor-specifi c antibodies in targeting antigen to human dendritic cells for cross-presentation. J. Immunol. 180 (11): 7687-7696 (2008).
42. Wang, R. F. and Wang, H. Y. Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells. Nat. Biotechnol. 20 (2): 149-154 (2002).
43. Reich, M., et al. Endocytosis targets exogenous material selectively to cathepsin S in live human dendritic cells. while cell penetrating peptides mediate nonselective transport to cysteine cathepsins. J. Leukocyte Biol. 81 (4): 990-1001 (2007).
44. Beerens, A. M., et al. Protein transduction domains and their utility in gene therapy. Curr. Gene Ther. 3 (5): 486-494 (2003).
45. Martin, M. E. and Rice, K. G. Peptide-guided gene delivery. AAPS J. 9 (1): E18-E29 (2007).
46. Meade, B. R. and Dowdy, S. F. Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides. Adv. Drug Deliv. Rev. 59 (2-3): 134-140 (2007).
47. Muratovska, A. and Eccles, M. R. Conjugate for effi cient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett. 558 (1-3): 63-68 (2004).
48. Davidson, T. J., et al. Highly effi cient small interfering RNA delivery to primary mammalian neurons induces MicroRNA-like effects before mRNA degradation. J. Neurosi. 24 (45): 10040-10046 (2004).
49. Chiu, Y. L., et al. Visualizing a correlation between siRNA localization. cellular uptake. and RNAi in living cells. Chem. Biol. 11 (8): 1165-1175 (2004).
50. Turner, J. J., et al. RNA targeting with peptide conjugates of oligonucleotides. siRNA and PNA. Blood Cells Molecules Diseases 38 (1): 1-7 (2007).
51. Turner, J. J., et al. Cell-penetrating peptide conjugates of peptide nucleic acids (PNA) as inhibitors of HIV-1 Tat-dependent trans-activation in cells. Nucleic Acids Res. 33 (21): 6837-6849 (2005).
52. Simeoni, F., et al. Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells. Nucleic Acids Res. 31 (11): 2717-2724 (2003).
53. Veldhoen, S., et al. Cellular delivery of small interfering RNA by a non-covalently attached cell-penetrating peptide: quantitative analysis of uptake and biological effect. Nucleic Acids Res. 34 (22): 6561-6573 (2006).
54. Lundberg, P., et al. Delivery of short interfering RNA using endosomolytic cell-penetrating peptides. FASEB J. 21 (11): 2664-2671 (2007).
55. Kumar, P., et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 448 (7149): 39-U2 (2007).
56. Kumar, P., et al. T cell-specifi c siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 134 (4): 577-586 (2008).
57. Shiraishi, T. and Nielsen, P. E. Photochemically enhanced cellular delivery of cell penetrating peptide-PNA conjugates. FEBS Lett. 580 (5): 1451-1456 (2006).
58. Lebleu, B., et al. Cell penetrating peptide conjugates of steric block oligonucleotides . Adv. Drug Deliv. Rev. 60 (4-5): 517-529 (2008).
59. Pooga, M., et al. Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat. Biotechnol. 16 (9): 857-861 (1998).
60. Abes, S., et al. Efficient splicing correction by PNA conjugation to an R6-Penetratin delivery peptide. Nucleic Acids Res. 35 (13): 4495-4502 (2007).
61. Resina, S., et al. Lipoplex and peptide-based strategies for the delivery of steric-block oligonucleotides. Int. J. Pharm. 344 (1-2): 96-102 (2007).
62. Bendifallah, N., et al. Evaluation of cell-penetrating peptides (CPPs) as vehicles for intracellular delivery of antisense peptide nucleic acid (PNA). Bioconjug. Chem. 17 (3): 750-758 (2006).
63. Wolf, Y., et al. Structural requirements for cellular uptake and antisense activity of peptide nucleic acids conjugated with various peptides. Biochemistry 45 (50): 14944-14954 (2006).
64. Kilk, K., et al. Evaluation of transportan 10 in PEI mediated plasmid delivery assay. J. Control. Release 103 (2): 511-523 (2005).
65. Ignatovich, I. A., et al. Complexes of plasmid DNA with basic domain 47-57 of the HIV-1 Tat protein are transferred to mammalian cells by endocytosis-mediated pathways. J. Biol. Chem. 278 (43): 42625-42636 (2003).
66. Eguchi, A., et al. Protein transduction domain of HIV-1 Tat protein promotes effi cient delivery of DNA into mammalian cells. J. Biol. Chem. 276 (28): 26204-26210 (2001).
67. Liu, Z. H., et al. Macro-branched cell-penetrating peptide design for gene delivery. J. Control. Release 102 (3): 699-710 (2005).
68. Torchilin, V. P., et al. TAT peptide on the surface of liposomes affords their effi cient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc. Nat. Acad. Sci. U.S.A. 98 (15): 8786-8791 (2001).
69. Zhang, C. L., et al. siRNA-containing liposomes modified with polyarginine effectively silence the targeted gene. J. Control. Release 112 (2): 229-239 (2006).
70. Nakamura, Y., et al. Octaarginine-modified multifunctional envelope-type nano device for siRNA. J. Control. Release 119 (3): 360-367 (2007).
71. Kleemann, E., et al. Nano-carriers for DNA delivery to the lung based upon a TAT-derived peptide covalently coupled to PEG-PEI. J. Control. Release 109 (1-3): 299-316 (2005).
72. Sethuraman, V. A. and Bae, Y. H. TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors. J. Control. Release 118 (2): 216-224 (2007).
73. Lewin, M., et al. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat. Biotechnol. 18 (4): 410-414 (2000).
74. Lagerholm, B. C. Peptide-mediated intracellular delivery of quantum dots. Methods Mol. Biol. 374: 105-112 (2007).
75. Torchilin, V. P. Tatp-mediated intracellular delivery of pharmaceutical nanocarriers . Biochem. Soc. Trans. 35 (Pt 4): 816-820 (2007).
76. Torchilin, V. P. Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv. Drug Deliv. Rev. 60 (4-5): 548-558 (2008).
77. Kale, A. A. and Torchilin, V. P. Design. synthesis. and characterization of pH-sensitive PEG-PE conjugates for stimuli-sensitive pharmaceutical nanocarriers: the effect of substitutes at the hydrazone linkage on the pH stability of PEG-PE conjugates. Bioconjug. Chem. 18 (2): 363-370 (2007).
78. Kale, A. A. and Torchilin, V. P. Enhanced transfection of tumor cells in vivo using "smart" pH-sensitive TAT-modified pegylated liposomes. J. Drug Target. 15 (7-8): 538-545 (2007).
79. Sawant, R. M., et al. "SMART" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjug. Chem. 17 (4): 943-949 (2006).
80. Lee, E. S., et al. Super pH-sensitive multifunctional polymeric micelle for tumor pHe specifi c TAT exposure and multidrug resistance. J. Control. Release 129 (3): 228-236 (2008).
81. Jones, A. T. Macropinocytosis: searching for an endocytic identity and role in the uptake of cell penetrating peptides. J. Cell. Mol. Med. 11 (4): 670-684 (2007).
82. Edenhofer, F. Protein transduction revisited: novel insights into the mechanism underlying intracellular delivery of proteins. Curr. Pharm. Design 14 (34): 3628-3636 (2008).
83. Derossi, D., et al. The 3rd helix of the antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. 269 (14): 10444-10450 (1994).
84. Elmquist, A., et al. VE-cadherin-derived cell-penetrating peptide. pVEC. with carrier functions. Exp. Cell Res. 269 (2): 237-244 (2001).
85. Foged, C. and Nielsen, H. M. Cell-penetrating peptides for drug delivery across membrane barriers. Expert Opin. Drug Deliv. 5 (1): 105-117 (2008).
86. Rothbard, J. B., et al. Role of membrane potential and hydrogen bonding in the mechanism of translocation of guanidinium-rich peptides into cells. J. Am. Chem. Soc. 126 (31): 9506-9507 (2004).
87. Wadia, J. S., Stan, R. V., and Dowdy, S. F. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat. Med. 10 (3): 310-315 (2004).
88. Conner, S. D. and Schmid, S. L. Regulated portals of entry into the cell. Nature. 422 (6927): 37-44 (2003).
89. Patel, L. N., Zaro, J. L., and Shen, W. C. Cell-penetrating peptides: intracellular pathways and pharmaceutical perspectives. Pharm. Res. 24 (11): 1977-1992 (2007).
90. Bareford, L. A., and Swaan, P. W. Endocytic mechanisms for targeted drug delivery. Adv. Drug Deliv. Rev. 59 (8): 748-758 (2007).
91. Cohen, F. S. and Melikyan, G. B. Implications of a fusion peptide structure. Nat. Struct. Biol. 8 (8): 653-655 (2001).
92. Han, X., et al. Membrane structure and fusion-triggering conformational change of the fusion domain from infl uenza hemagglutinin. Nat. Struct. Biol. 8 (8): 715-720 (2001).
93. Madhusoodanan, M. and Lazaridis, T. Investigation of pathways for the low-pH conformational transition in infl uenza hemagglutinin. Biophysi. J. 84 (3): 1926-1939 (2003).
94. Cho, Y. W., Kim, J. D., and Park, K. Polycation gene delivery systems: escape from endosomes to cytosol. J. Pharmacy Pharmacol. 55 (6): 721-734 (2003).
95. Fretz, M. M., et al. Temperature-, concentration-and cholesterol-dependent translocation of l-and d-octa-arginine across the plasma and nuclear membrane of CD34+leukaemia cells. Biochemi. J. 403 (2): 335-342 (2007).
96. Takeuchi, T., et al. Direct and rapid cytosolic delivery using cell-penetrating peptides mediated by pyrenebutyrate. ACS Chem. Biol. 1 (5): 299-303 (2006).
97. Duchardt, F., et al. A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffi c. 8 (7): 848-866 (2007).
98. Nakase, I., et al. Methodological and cellular aspects that govern the internalization mechanisms of arginine-rich cell-penetrating peptides. Adv. Drug Deliv. Rev. 60 (4-5): 598-607 (2008).
99. Rothbard, J. B., Jessop, T. C., and Wender, P. A. Adaptive translocation: the role of hydrogen bonding and membrane potential in the uptake of guanidinium-rich transporters into cells. Adv. Drug Deliv. Rev. 57 (4): 495-504 (2005).
100. Zaro, J. L. and Shen, W. C. Evidence that membrane transduction of oligoarginine does not require vesicle formation. Exp. Cell Res. 307 (1): 164-173 (2005).
101. Afonin, S., et al. The cell-penetrating peptide TAT(48-60) induces a non-lamellar phase in DMPC membranes. Chemphyschem. 7 (10): 2134-2142 (2006).
102. Fischer, R., et al. A stepwise dissection of the intracellular fate of cationic cell-penetrating peptides. J. Biol. Chem. 279 (13): 12625-12635 (2004).
103. Al Taei, S., et al. Intracellular traffi c and fate of protein transduction domains HIV-1 TAT peptide and octaarginine. Implications for their utilization as drug delivery vectors. Bioconjug. Chem. 17 (1): 90-100 (2006).
104. Tarrago-Trani, M. T. and Storrie, B. Alternate routes for drug delivery to the cell interior: pathways to the Golgi apparatus and endoplasmic reticulum. Adv. Drug Deliv. Rev. 59 (8): 782-797 (2007).
105. Foerg, C., et al. Differentiation restricted endocytosis of cell penetrating peptides in MDCK cells corresponds with activities of Rho-GTPases. Pharm. Res. 24 (4): 628-642 (2007).
106. Su, Y., et al. Roles of arginine and lysine residues in the translocation of a cell-penetrating peptide from (13)C, (31)P. and (19)F solid-state NMR. Biochemistry 48 (21): 4587-4595 (2009).
107. Wender, P. A., et al. The design of guanidinium-rich transporters and their internalization mechanisms. Adv. Drug Deliv. Rev. 60 (4-5): 452-472 (2008).
108. Amand, H. L., et al. Stimulated endocytosis in penetratin uptake: effect of arginine and lysine. Biochem. Biophys. Res. Commun. 371 (4): 621-625 (2008).
109. Palm, C., et al. Peptide degradation is a critical determinant for cell-penetrating peptide uptake. Biochim. Biophys. Acta 1768 (7): 1769-1776 (2007).
110. Pujals, S. and Giralt, E. Proline-rich. amphipathic cell-penetrating peptides. Adv. Drug Deliv. Rev. 60 (4-5): 473-484 (2008).
111. Foged, C., et al. Cellular uptake and membrane-destabilising properties of alpha-peptide/beta-peptoid chimeras: lessons for the design of new cell-penetrating peptides. Biochim. Biophys. Acta Biomembranes 1778 (11): 2487-2495 (2008).
112. Foerg, C., et al. Decoding the entry of two novel cell-penetrating peptides in HeLa cells: Lipid raft-mediated endocytosis and endosomal escape. Biochemistry 44 (1): 72-81 (2005).
113. Dom, G., et al. Cellular uptake of Antennapedia Penetratin peptides is a two-step process in which phase transfer precedes a tryptophan-dependent translocation. Nucleic Acids Res. 31 (2): 556-561 (2003).
114. Letoha, T., et al. Investigation of penetratin peptides. Part 2. In vitro uptake of penetratin and two of its derivatives. J. Peptide Sci. 11 (12): 805-811 (2005).
115. Fischer, P. M., et al. Structure-activity relationship of truncated and substituted analogues of the intracellular delivery vector Penetratin. J. Peptide Res. 55 (2): 163-172 (2000).
116. Abes, R., et al. Arginine-rich cell penetrating peptides: design. structure-activity. and applications to alter pre-mRNA splicing by steric-block oligonucleotides. J. Peptide Sci. 14 (4): 455-460 (2008).
117. Mae, M., et al. A stearylated CPP for delivery of splice correcting oligonucleotides using a non-covalent co-incubation strategy. J. Control. Release 134 (3): 221-227 (2009).
118. Kim, W. J., et al. Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma. Mol. Ther. 14 (3): 343-350 (2006).
119. Gump, J. M. and Dowdy, S. F. TAT transduction: the molecular mechanism and therapeutic prospects. Trends Mol. Med. 13 (10): 443-448 (2007).
120. Deshayes, S., et al. Structural polymorphism of two CPP: an important parameter of activity. Biochim. Biophys. Acta Biomembranes 1778 (5): 1197-1205 (2008).
121. Prochiantz, A. Protein and peptide transduction. twenty years later a happy birthday. Adv. Drug Deliv. Rev. 60 (4-5): 448-451 (2008).
122. Khalil, I. A., et al. Octaarginine-modified liposomes: enhanced cellular uptake and controlled intracellular traffi cking. Int. J. Pharm. 354 (1-2): 39-48 (2008).
123. Torchilin, V. P. Cell penetrating peptide-modified pharmaceutical nanocarriers for intracellular drug and gene delivery. Biopolymers 90 (5): 604-610 (2008).
124. Saalik, P., et al. Protein cargo delivery properties of cell-penetrating peptides. A comparative study. Bioconjug. Chem. 15 (6): 1246-1253 (2004).
125. Lundin, P., et al. Distinct uptake routes of cell-penetrating peptide conjugates. Bioconjug. Chem. 19 (12): 2535-2542 (2008).
126. Bolton, S. J., et al. Cellular uptake and spread of the cell-permeable peptide penetratin in adult rat brain. Eur. J. Neurosi. 12 (8): 2847-2855 (2000).
127. Melikov, K. and Chernomordik, L. Arginine-rich cell penetrating peptides: from endosomal uptake to nuclear delivery. Cell. Mol. Life Sci. 62 (23): 2739-2749 (2005).
128. Waizenegger, T., Fischer, R., and Brock, R. Intracellular concentration measurements in adherent cells: a comparison of import effi ciencies of cell-permeable peptides. Biol. Chem. 383 (2): 291-299 (2002).
129. Fischer, R., et al. A quantitative validation of fluorophore-labelled cell-permeable peptide conjugates: fluorophore and cargo dependence of import. Biochim. Biophys. Acta Biomembranes 1564 (2): 365-374 (2002).
130. Kilk, K., et al. Cellular internalization of a cargo complex with a novel peptide derived from the third helix of the islet-1 homeodomain. Comparison with the penetratin peptide. Bioconjug. Chem. 12 (6): 911-916 (2001).
131. Palm-Apergi, C., et al. The membrane repair response masks membrane disturbances caused by cell-penetrating peptide uptake. FASEB J. 23 (1): 214-223 (2009).
132. Magzoub, M., Eriksson, L. E. G., and Graslund, A. Comparison of the interaction. positioning. structure induction and membrane perturbation of cell-penetrating peptides and non-translocating variants with phospholipid vesicles. Biophys. Chem. 103 (3): 271-288 (2003).
133. Christiaens, B., et al. Tryptophan fluorescence study of the interaction of penetratin peptides with model membranes. Eur. J. Biochem. 269 (12): 2918-2926 (2002).
134. Saar, K., et al. Cell-penetrating peptides: a comparative membrane toxicity study. Anal. Biochem. 345 (1): 55-65 (2005).
135. Orzaez, M., et al. Conjugation of a novel Apaf-1 inhibitor to peptide-based cell-membrane transporters: effective methods to improve inhibition of mitochondria-mediated apoptosis. Peptides 28 (5): 958-968 (2007).
136. Maiolo, J. R., Ferrer, M., and Ottinger, E. A. Effects of cargo molecules on the cellular uptake of arginine-rich cell-penetrating epeptides. Biochim. Biophys. Acta 1712 (2): 161-172 (2005).
137. Trehin, R., et al. Cellular internalization of human calcitonin derived peptides in MDCK monolayers: a comparative study with Tat(47-57) and penetratin(43-58). Pharm. Res. 21 (1): 33-42 (2004).
138. Morishita, M., et al. A novel approach using functional peptides for effi cient intestinal absorption of insulin. J. Control. Release 118 (2): 177-184 (2007).
139. Liang, J. F. and Yang, V. C. Insulin-cell penetrating peptide hybrids with improved intestinal absorption effi ciency. Biochem. Biophys. Res. Commun. 335 (3): 734-738 (2005).
140. Wang, H. Y., et al. Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. J. Clin. Invest. 109 (11): 1463-1470 (2002).
141. Rothbard, J. B., et al. Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of infl ammation. Nat. Med. 6 (11): 1253-1257 (2000).
142. Shiraishi, T., Pankratova, S., and Nielsen, P. E. Calcium ions effectively enhance the effect of antisense peptide nucleic acids conjugated to cationic tat and oligoarginine peptides. Chem. Biol. 12 (8): 923-929 (2005).
143. El Andaloussi, S., et al. Induction of splice correction by cell-penetrating peptide nucleic acids. J. Gene Med. 8 (10): 1262-1273 (2006).
144. Yang, S., et al. Cellular uptake of self-assembled cationic peptide-DNA complexes: Multifunctional role of the enhancer chloroquine. J. Control. Release 135 (2): 159-165 (2009).
145. Abes, S., et al. Endosome trapping limits the effi ciency of splicing correction by PNA-oligolysine conjugates. J. Control. Release 110 (3): 595-604 (2006).
146. Khalil, I. A., et al. Octaarginine-modified multifunctional envelope-type nanoparticles for gene delivery. Gene Ther. 14 (8): 682-689 (2007).
147. Suzuki, R., Yamada, Y., and Harashima, H. Development of small. homogeneous pDNA particles condensed with mono-cationic detergents and encapsulated in a multifunctional envelope-type nano device. Biol. Pharm. Bull. 31 (6): 1237-1243 (2008).
148. Mudhakir, D., et al. A novel IRQ ligand-modified nano-carrier targeted to a unique pathway of caveolar endocytic pathway. J. Control. Release 125 (2): 164-173 (2008).
149. Nakamura, T., et al. Efficient MHC class I presentation by controlled intracellular traffi cking of antigens in octaarginine-modified liposomes. Mol. Ther. 16 (8): 1507-1514 (2008).
150. Lo, S. L. and Wang, S. An endosomolytic Tat peptide produced by incorporation of histidine and cysteine residues as a nonviral vector for DNA transfection. Biomaterials 29 (15): 2408-2414 (2008).
151. Ohmori, N., et al. The enhancing effect of anionic alpha-helical peptide on cationic peptide-mediating transfection systems. Biochem. Biophys. Res. Commun. 235 (3): 726-729 (1997).
152. Michiue, H., et al. Ubiquitination-resistant p53 protein transduction therapy facilitates anti-cancer effect on the growth of human malignant glioma cells. FEBS Lett. 579 (18): 3965-3969 (2005).
153. Sasaki, K., et al. An artifi cial virus-like nano carrier system: enhanced endosomal escape of nanoparticles via synergistic action of pH-sensitive fusogenic peptide derivatives. Anal. Bioanal. Chem. 391 (8): 2717-2727 (2008).
154. Min, S. H., et al. A composite gene delivery system consisting of polyethylenimine and an amphipathic peptide KALA. J. Gene Med. 8 (12): 1425-1434 (2006).
155. Sirsi, S. R., et al. Functionalized PEG-PEI copolymers complexed to exon-skipping oligonucleotides improve dystrophin expression in mdx mice. Hum. Gene Ther. 19 (8): 795-806 (2008).
156. Doyle, S. R. and Chan, C. K. Differential intracellular distribution of DNA complexed with polyethylenimine (PEI) and PEI-polyarginine PTD infl uences exogenous gene expression within live COS-7 cells. Genetic Vaccines Ther. 5: 11 (2007).
157. Huang, R. Q., Pei, Y. Y., and Jiang, C. Enhanced gene transfer into brain capillary endothelial cells using Antp-modified DNA-loaded nanoparticles. J. Biom. Sci. 14 (5): 595-605 (2007).
158. Juliano, R. L. Intracellular delivery of oligonucleotide conjugates and dendrimer complexes. Ann. N.Y. Acad. Sci. 1082: 18-26 (2006).